RIVANNA Secures FDA 510(k) Clearance for AI-Ready Accuro XV Musculoskeletal Ultrasound Platform

New updates have been reported about RIVANNA.

RIVANNA has obtained U.S. Food and Drug Administration 510(k) clearance for its Accuro XV Diagnostic Ultrasound System, enabling commercial deployment for musculoskeletal imaging in hospitals and clinics. The clearance validates the company’s core AI-centric platform strategy and opens a new point-of-care segment in extremity injury triage where few targeted solutions currently exist.

Built around a conformable three-dimensional volumetric probe, Accuro XV automates wide field-of-view B-mode image acquisition over a 10 cm scan extent and is mounted on a cart-based, battery-powered system with touchscreen control and DICOM-compatible archiving. RIVANNA positions this configuration to reduce reliance on traditional radiography in high-volume emergency settings by bringing portable, radiation-free imaging to the bedside.

The company is concurrently advancing AI decision-support modules for Accuro XV, including BoneEnhance, which segments musculoskeletal anatomy to improve 3D visualization of skeletal structures, and CADe/x, an algorithm designed to automatically flag potential fractures from volumetric ultrasound data. Both modules are being trained and validated in an eight-center clinical study, providing a data and evidence engine that could reinforce RIVANNA’s regulatory and commercial moat if performance targets are met.

Management characterizes the FDA decision as an inflection point, confirming that the underlying AI architecture, imaging hardware, and regulatory pathway are scalable across multiple clinical indications. This platform approach aims to support RIVANNA’s broader strategy of extending beyond regional anesthesia into fracture care, with both application areas targeting large addressable markets and benefiting from shared technology and IP across more than 100 patents.

Operationally, Accuro XV is designed to support task-shifting in emergency and urgent care workflows, as highlighted by a published feasibility study showing that non-physician operators can produce diagnostic-quality extremity images after roughly one hour of training, with more than 90% of scans deemed adequate for interpretation. If reflected in real-world adoption, this could lower staffing constraints, shorten time-to-diagnosis, and lessen imaging bottlenecks, particularly in resource-limited or surge conditions.

RIVANNA’s Accuro XV program has received support from the U.S. Department of Health and Human Services and BARDA under a federal preparedness contract, signaling strategic relevance to emergency readiness and mass-casualty planning. For investors and partners, the clearance de-risks a key product in RIVANNA’s portfolio, establishes regulatory validation of its AI-enabled ultrasound platform, and sets the stage for commercialization and subsequent AI-module clearances that could drive incremental revenue and expand the company’s footprint in point-of-care imaging.